Healthcare & Life Sciences
AltruBio
Israel
aliveseries-b
series-b
Stage
1
Investors
About
AltruBio develops antibody therapeutics that target a novel immune system regulator to selectively remove chronically over-activated T cells involved in autoimmune and inflammatory diseases, with pipeline programs for acute graft-versus-host disease and ulcerative colitis.
Explore AltruBio's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.